References
- Brogden R. N., McTavish D. Acrivastine: review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs 1991; 41: 927–940
- Simons F. E.R., Simons K. J. The pharmacology and use of H1‐receptor antagonist drugs. N. Engl. J. Med. 1994; 330: 1663–1670
- Simons F. E.R., Simons K. J. Clinical pharmacology of new histamine H1‐receptor antagonists. Clin. Pharmacokinet. 1999; 36: 329–352
- Simpson K., Jarvis B. Fexofenadine: review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000; 59: 301–321
- Gonzalez M. A., Estes K. S. Pharmacokinetic overview of oral second‐generation H1 antihistamines. Int. J. Clin. Pharmacol. Ther. 1998; 36: 292–300
- Pade V., Aluri J., Manning L., Stavchansky S. Bioavailability of pseudoephedrine from controlled release formulations in the presence of guaifenesin in human volunteers. Biopharm. Drug Dispos. 1995; 16: 381–391
- Makhija S. N., Vavia P. R. Controlled porosity osmotic pump‐based controlled release systems of pseudoephedrine I. Cellulose acetate as a semipermeable membrane. J. Control. Release 2003; 89: 5–18
- Rudnic E., Schwartz J. B. Oral solid dosage forms. Remington's Pharmaceutical Sciences18th Ed., A. R. Gennaro. Mack Publishing Co., Pennsylvania 1990; 1633–1665
- Vergote G. J., Vervaet C., Van‐Driessche I., Hoste S., Remon J. P. Oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen. Int. J. Pharm. 2001; 219: 81–87
- Talukdar M. M., Rombaut P., Kinget R. Release mechanism of an oral controlled‐release delivery system for indomethacin. Pharm. Dev. Technol. 1998; 3: 1–6
- Gu X., MacNair K. R., Simons F. E.R., Simons K. J. Simultaneous HPLC determination of the H1‐antagonist acrivastine and the decongestant pseudoephedrine. AAPS Pharm Sci 1999; 1(Suppl 4)S‐2742
- Hixson A. W., Crowell J. H. Dependence of reaction velocity upon surface and agitation I. Theoretical consideration. Ind. Eng. Chem. 1931; 23: 923–931
- Tahara K., Yamamoto K., Nishihata T. Overall mechanism behind matrix sustained release (SR) tablets prepared with hydroxypropyl methylcellulose. J. Control. Release 1995; 35: 59–66
- Peppas N. A., Ritger P. L. A simple equation for description of solute release I. Fickian and non‐Fickian release from non‐swellable devices in the form of slabs, spheres, cylinders or disc. J. Control. Release 1987; 5: 23–36
- Peppas N. A., Ritger P. L. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Control. Release 1987; 5: 37–42
- Korsmeyer R. W., Gurny R., Doelker F., Buri P., Peppas N. A. Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm. 1983; 15: 25–35
- Khan K. A. The concept of dissolution efficiency. J. Pharm. Pharmacol. 1975; 27: 48–49
- Efentakis M., Koutlis A. Release of furosemide from multiple‐unit and single‐unit preparations containing different viscosity grades of sodium alginate. Pharm. Dev. Technol. 2001; 6: 91–98
- Li S. P., Feld K. M., Kowarski C. R. Preparation and evaluation of Eudragit® acrylic resin for controlled drug release of pseudoephedrine hydrochloride. Drug Dev. Ind. Pharm. 1991; 17: 1655–1683
- William R. O., Reynolds T. D., Cabelka T. D., Sykora M. A., Mahaguna V. Investigation of excipient type and level on drug release from controlled release tablets containing HPMC. Pharm. Dev. Technol. 2002; 7: 181–193
- Zhang Y. E., Schwartz J. B. Melt granulation and heat treatment for wax matrix‐controlled drug release. Drug Dev. Ind. Pharm. 2003; 29: 131–138
- Barthelemy P., Laforet J. P., Farah N., Joachim J. Compritol® 888ATO: an innovative hot‐melt coating agent for prolonged‐release drug formulations. Eur. J. Pharm. Biopharm. 1999; 47: 87–90
- Tiwari S. B., Murthy T. K., Pai M. R., Mehta P. R., Chowdary P. B. Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system. AAPS PharmSciTech 2003; 4(3), Article 31